Company Receives CE Mark Approval for 29 mm Transfemoral System First Human Experience With Next-Generation Valve Platforms to Be Presented PARIS-- Edwards Lifesciences Corporation, the global leader ...

Edwards today presented new data at New York Valves 2026 supporting its transcatheter aortic valve replacement (TAVR) ...

MIAMI, FL.-- Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced three-year results of a pivotal clinical study of inoperable ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment ...

LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...

Edwards Lifesciences might be a pioneer in the transcatheter aortic valve replacement market, but that doesn’t mean it’s smooth sailing in the space. The Irvine, CA-based company faces stiff ...

July 18, 2011 (Gaithersburg, Maryland) — The Sapien transcatheter heart valve (Edwards Lifesciences) was associated with "an impressive reduction of mortality . . . relative to the heterogenous ...

Edwards Lifesciences Corp.’s next generation of less-invasive heart valves is making its domestic debut, providing a boost that has extended a monthslong rally for shares of the Irvine-based heart ...

Edwards Lifesciences said it is delaying the launch of the Sapien 3 Ultra transcatheter aortic valve replacement (TAVR) System in Europe until later this year. The Irvine, CA-based company said it ...

Review staff from the US Food and Drug Administration (FDA) said Edwards Lifesciences' Sapien Transcatheter Heart Valve (THV) met trial endpoints for safety and effectiveness for the treatment of high ...